EUVIMEDEUVIMED entdecken
Open Access

Risk factors for type I leptomeningeal metastasis derived from non-small cell lung cancer and the impact of treatment for brain metastases on its development

Toshihiko Iuchi iD, Masato Shingyoji, Satoko Mizuno, Hironori Ashinuma, Yuzo Hasegawa, Taiki Setoguchi, Junji Hosono, Tsukasa Sakaida

Neuro-Oncology Practice · 04.06.2025 · 12 (3) · 448-457

DOI: 10.1093/nop/npae118 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuro-Oncology Practice, online erschienen am 03.12.2024. Verfasst von Toshihiko Iuchi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Neurological Surgery, Chiba Cancer Center, Chiba, Japan. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: KAKENHI.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Preventing Type I leptomeningeal metastasis (LM) is critical when treating brain metastases (BMs). The aim of this study was to extract risk factors for Type I LM and to clarify the optimal treatment for BMs from the perspective of Type I LM prevention.

Methods

The clinical course of consecutive cases of BMs derived from non-small cell lung cancer (NSCLC) treated at our hospital was retrospectively evaluated. The relationship between clinicopathological factors, including molecular background, and Type I LM development was verified. In addition, the difference in the time to Type I LM because of treatment for BMs was evaluated to clarify the effectiveness of each treatment in preventing Type I LM.

Results

Of 784 patients with BMs, 44 exhibited Type I LM at the onset of BMs. Poor performance status (P < .0001) and mutated epidermal growth factor receptor (EGFR) gene (P = .004) were significant risk factors for Type I LM. Among the 740 patients without LMC at diagnosis, 85 developed Type I LM. Younger age (P = .011) and mutated EGFR (P < .0001) were risk factors for developing LMC after BMs. Osimertinib reduced the incidence of Type I LM (hazard ratio [HR]: 0.48; 95% confidence interval [CI]: 0.24-0.97) in EGFR-mutated cases. Immune checkpoint inhibitors (ICIs) showed a tendency to prolong the time to Type I LM (HR: 0.15; 95% CI: 0.02-1.11) in EGFR-wild-type cases.

Conclusions

Patients with EGFR-mutated NSCLC are prone to developing Type I LM. Osimertinib for EGFR-mutated cases and ICIs are expected to prevent Type I LM after the diagnosis of BMs.

Schlagwörter

Stichwörter der Autor:innen

EGFRimmune checkpoint inhibitorleptomeningeal metastasisnon-small cell lung cancertyrosine kinase inhibitor

Autor:innen und Institutionen

  • Division of Neurological Surgery, Chiba Cancer Center, Chiba, Japan.
  • Division of Respirology, Chiba Cancer Center, Chiba, Japan.

ORCID-Profile: Toshihiko Iuchi

Förderung

  • KAKENHI

Zitieren

APA

Iuchi, T., Shingyoji, M., Mizuno, S., Ashinuma, H., Hasegawa, Y., Setoguchi, T., Hosono, J., & Sakaida, T. (2025). Risk factors for type I leptomeningeal metastasis derived from non-small cell lung cancer and the impact of treatment for brain metastases on its development. Neuro-Oncology Practice, 12(3), 448-457. https://doi.org/10.1093/nop/npae118

Vancouver

Iuchi T, Shingyoji M, Mizuno S, Ashinuma H, Hasegawa Y, Setoguchi T, et al. Risk factors for type I leptomeningeal metastasis derived from non-small cell lung cancer and the impact of treatment for brain metastases on its development. Neuro-Oncology Practice. 2025;12(3):448-457. doi:10.1093/nop/npae118

BibTeX
@article{Iuchi2025,
  author = {Iuchi, Toshihiko and Shingyoji, Masato and Mizuno, Satoko and Ashinuma, Hironori and Hasegawa, Yuzo and Setoguchi, Taiki and Hosono, Junji and Sakaida, Tsukasa},
  title = {Risk factors for type I leptomeningeal metastasis derived from non-small cell lung cancer and the impact of treatment for brain metastases on its development},
  journal = {Neuro-Oncology Practice},
  year = {2025},
  volume = {12},
  number = {3},
  pages = {448--457},
  doi = {10.1093/nop/npae118}
}
Kostenlos starten →